Analyzing Qiagen (QGEN) and WuXi PharmaTech (Cayman) (WX)
Qiagen (NASDAQ: QGEN) and WuXi PharmaTech (Cayman) (NYSE:WX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
This table compares Qiagen and WuXi PharmaTech (Cayman)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|WuXi PharmaTech (Cayman)||7.52%||6.93%||4.67%|
61.4% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Qiagen and WuXi PharmaTech (Cayman)’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Qiagen||$1.34 billion||5.59||$80.40 million||$0.39||84.10|
|WuXi PharmaTech (Cayman)||N/A||N/A||N/A||$1.18||38.91|
Qiagen has higher revenue and earnings than WuXi PharmaTech (Cayman). WuXi PharmaTech (Cayman) is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Qiagen and WuXi PharmaTech (Cayman), as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|WuXi PharmaTech (Cayman)||0||0||0||0||N/A|
Qiagen currently has a consensus price target of $34.00, suggesting a potential upside of 3.66%. Given Qiagen’s higher possible upside, analysts plainly believe Qiagen is more favorable than WuXi PharmaTech (Cayman).
Qiagen beats WuXi PharmaTech (Cayman) on 8 of the 10 factors compared between the two stocks.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About WuXi PharmaTech (Cayman)
WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.